This study has some limitations: first, the intrinsic limitations of retrospective reviews, replete with non-standardized response assessment, toxicity reporting and variable follow-up intervals; and second, the small size of this ROS1-rearranged population due to the relative rarity of ROS1-rearrangements within NSCLC populations. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.